HCV Detection, Discrimination, and Genotyping Technologies

Warkad, Shrikant Dashrath; Nimse, Satish Balasaheb; Song, Ki-Bong; Kim, Taisun

doi:10.3390/s18103423

Cited by 31 publications

(30 citation statements)

References 127 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a number of clinical practices have shown that the validation of HCV subtype plays a crucial role in determining the appropriate treatment for HCV. Thus, various methods for HCV genotyping have been developed (19). The present study successfully mitigates some of the problems inherent in HCV genotyping by using RT-qPCR.…”

Section: Discussionmentioning

confidence: 97%

Development and validation of a simple and rapid method for hepatitis�C virus genotyping based on one‑step RT‑qPCR

Yang

Ding

Huang³

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infections caused by different subtypes require different treatments; therefore, rapid and cost-effective genotyping methods for the diagnosis of HCV are greatly needed. In the present study, a new method to diagnose HCV subtypes that depends on a one-step quantitative reverse transcription PCR (RT-qPCR) and TaqMan fluorescence probe technique is described. Five pairs of primers and five probes were designed, which were able to detect five genotypes in three reaction tubes. One reaction was used to detect the 1b subtype, one was used to detect the 2a and 6a subtypes, and the other was used to detect the 3a and 3b subtypes. Rigorous performance validation was implemented for five aspects: Precision, sensitivity, accuracy, specificity and anti-interference. The HCV subtype that infected 289 patients was evaluated in the present study via RT-qPCR and verified by sequencing. The results revealed that the 1b subtype accounted for 45% of infections, the 2a subtype accounted for 9% of infections, the 3a subtype accounted for 13% of infections, the 3b subtype accounted for 18% of infections, and the 6a subtype accounted for 15% of infections. The analytical sensitivity for the detection of each of the five HCV subtypes was 1,000 IU/ml. The new method performed well in the performance validation mentioned above, indicating its effectiveness as a HCV genotyping method. RT-qPCR has mitigated some of the former challenges of existing HCV genotyping methods, including the time commitment, expense, and inaccuracy of such methods. The performance validation of this new method showed that RT-qPCR is reliable enough to be widely applied in China for HCV genotyping.

show abstract

Section: Discussionmentioning

confidence: 97%

Development and validation of a simple and rapid method for hepatitis�C virus genotyping based on one‑step RT‑qPCR

Yang

Ding

Huang³

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…[ 3 ] There are several techniques used to HCV GT determination in the clinical practice, including real-time PCR, line-probe assay, heteroduplex mobility analysis, restriction fragment length polymorphism. [ 10 , 11 , 16 ] The currently available commercial techniques for HCV GT 1 failed in 2% to 16% patients. [ 16 , 17 ] In a large CHC cohort of 8,945 patients from phase II/III DAAs clinical trials, Tania Welzel [ 10 ] et al compared HCV GT and subtypes with INNO-LiPA 2.0 vs amplicon sequencing.…”

Section: Discussionmentioning

confidence: 99%

“…[ 10 ] Hence, the sequence analysis is still the golden standard method for HCV determination, but due to the longer time and higher cost for test, and required professional equipment, the widespread application for this technology was limited. [ 10 , 11 ] Currently, pangenotypic DAAs are available in numerous countries, the use of which should be prioritised because they achieve high treatment efficacy across all 6 major HCV GTs. Treatment with pangenotypic DAAs can be initiated without determination of the GT and subtype in the regions where GT test is not available and/or not affordable, or to simplify therapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination

Li¹,

Jiang

et al. 2020

Medicine

View full text Add to dashboard Cite

Several new, pangenotypic direct-acting antiviral agents (DAAs) have been approved, may reduce the need for genotyping to guide therapy decisions for patients with chronic hepatitis C (CHC). This study aimed to investigate the efficacy and safety of Sofosbuvir (SOF)-based pangenotypic DAAs therapy for CHC patients without genotype (GT determination in the real-world practice. This retrospective cohort study included treatment-naïve CHC patients without GT determination, who received SOF-based DAAs therapy, including 400 mg SOF plus 60 mg daclatasvir (DCV) daily or 400 mg SOF plus 100 mg velpatasvir (VEL) daily for 12 or 24 weeks. Clinical and laboratory data, including sustained virologic response (SVR), were obtained at baseline, end of treatment (EOT), 12 weeks after EOT, and 48 weeks after EOT. A total of 95 CHC patients, including 30 (31.58%) had liver cirrhosis were enrolled. SVR rates after 12 weeks of treatment (SVR12) was 96.84% (92/95), including 96.20% (76/79) of patients receiving SOF plus DCV and 100% (16/16) of patients receiving SOF plus VEL. For 92 patients achieving an SVR12, no virological relapse was observed at 48 weeks after EOT. Furthermore, serum evaluation of liver fibrosis aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 score were decreased significantly at EOT and 12 weeks after EOT, compared to pre-treatment values (both P < .05). Treatment was well-tolerated by our patients. SOF-based pangenotypic DAAs including SOF plus DCV and SOF plus VEL, were effective and safe for CHC patients without GT determination in this study. This may provide a potential simple strategy for CHC treatment without GT determination.

show abstract

“…Hepatitis C is an infective illness induced by the hepatitis C virus (HCV), which is a viral RNA of the family Flaviviridae. When HCV infection is screened by simple and rapid techniques with high sensitivity and specificity, it can assist to control the encumbrance on HCV health care globally [ 74 ]. Fan et al.…”

Section: Application Of Carbon Nanomaterials For Viral Diagnosismentioning

confidence: 99%

Application of carbon nanomaterials in human virus detection

Ehtesabi

2020

Journal of Science: Advanced Materials and Devices

View full text Add to dashboard Cite

Human-pathogenic viruses are still a chief reason for illness and death on the globe, as epitomized by the COVID-19 pandemic instigated by a coronavirus in 2020. Multiple novel sensors have been invented because diseases must be detected and diagnosed as early as possible, and recognition methods have to be carried out with minimal invasivity. Sensors have been particularly developed focusing on miniaturization by the use of nanomaterials for fabricating nanosensors. The nano-sized nature of nanomaterials and their exclusive optical, electronical, magnetical, and mechanical attributes can enhance patient care through the use of sensors with minimal invasivity and extreme sensitivity. Amongst the nanomaterials utilized for fabricating nano-sensors, carbon-based nanomaterials are promising as these sensors respond better to signals in various sensing settings. This review provides an overview of the recent developments in carbon nanomaterial-based biosensors for viral recognition based on the biomarkers that arise from the infection, the nucleic acids from the viruses, and the entire virus. The role of carbon nanomaterials is highlighted by the improvement of sensor and recognition functionality. The Dengue virus, Ebola virus, Hepatits virus, human immunodeficiency virus (HIV), influenza virus, Zika virus and Adenovirus are the virus types reviewed to illustrate the implementation of the techniques. Finally, the drawbacks and advantages of carbon nanomaterial-based biosensors for viral recognition are identified and discussed.

show abstract

HCV Detection, Discrimination, and Genotyping Technologies

Cited by 31 publications

References 127 publications

Development and validation of a simple and rapid method for hepatitis�C virus genotyping based on one‑step RT‑qPCR

Development and validation of a simple and rapid method for hepatitis�C virus genotyping based on one‑step RT‑qPCR

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination

Application of carbon nanomaterials in human virus detection

Contact Info

Product

Resources

About